Table 2.
£ Patients (n = 168) | Controls (n = 168) | |||||||||
Male* | Female* | p-value¥ | Male* | Female* | p-value¥ | |||||
ABO* | n | % | n | % | n | % | n | % | ||
Total | 54 | 100.0 | 114 | 100.0 | 54 | 32.1 | 114 | 67.9 | ||
A | 11 | 20.4 | 42 | 36.8 | 0.034 | 22 | 40.7 | 46 | 40.3 | 1.000 |
B | 3 | 5.6 | 15 | 13.2 | 1.184 | 7 | 12.9 | 14 | 12.3 | 1.000 |
AB | 1 | 1.8 | 2 | 1.8 | 1.000 | 2 | 3.7 | 6 | 5.3 | 1.000 |
O | 39 | 72.2 | 55 | 48.2 | 0.004 | 23 | 42.6 | 48 | 42.1 | 1.000 |
¥ Calculated using Fisher's exact test
*For all ABO histo-blood group phenotypes from male and female patients (χ2: 8.895; DF: 3; p-value = 0.030) For all ABO histo-blood group phenotypes from male patients and male controls (χ :29.729; DF: 3; p-value = 0.021)
£Patients (Aversus non-A): adjusted OR: 0.438, IC 95%: 0.201 - 0.941; p-value = 0.034
£Patients (O versus non-O): adjusted OR: 2.789, IC 95%: 1.385 - 5.616; p-value = 0.004